The inhibition of the LAT1 amino acid transporter effectively blocks IL-17 and IL-22 secretion by Th17 and γδ T cells, thus preventing imiquimod (IMQ) and IL-23-induced skin inflammation [83]. Here, IL17A is linked to dermatitis.